BI 860585

Drug Profile

BI 860585

Alternative Names: BI-860585

Latest Information Update: 06 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Boehringer Ingelheim Pharmaceuticals; Evotec AG
  • Developer Boehringer Ingelheim Pharmaceuticals
  • Class Antineoplastics; Small molecules
  • Mechanism of Action MTORC1 protein inhibitors; MTORC2 protein inhibitors; Protein-serine-threonine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 27 Apr 2017 Boehringer Ingelheim Pharmaceuticals completes a phase I trial in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Belgium and Italy (NCT01938846)
  • 01 Apr 2016 Phase-I development is ongoing in Belgium and Italy
  • 23 Sep 2013 Phase-I clinical trials in Solid tumours (late-stage disease, metastatic disease, second-line therapy or greater) in Italy & Belgium (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top